Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
AI-Driven Wellness Play on the CSE (click to learn more) Golden Cariboo (CSE:GCC) (OTC:GCCFF) Unlocks Cariboo Gold Potential (click to learn more) An Emerging Name in Cannabis: HERB (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Bavarian Nordic AS (PK) BVNKF

Alternate Symbol(s):  BVNRY

Healthcare Biotechnology
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (PINL:BVNKF)

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

GlobeNewswire February 15, 2023

Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen

GlobeNewswire February 21, 2019

Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial

GlobeNewswire January 25, 2019

Bavarian Nordic Advances Development of Equine Encephalitis Virus Vaccine

GlobeNewswire January 24, 2019

Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government under Contract for Freeze-dried MVA-BN® Smallpox Vaccine

GlobeNewswire January 18, 2019

Bavarian Nordic Announces FDA Acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine

GlobeNewswire December 21, 2018

Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers

GlobeNewswire November 2, 2018

Bavarian Nordic Announces Initiation of Phase 2 Trial of BN-Brachyury for the Treatment of Chordoma

GlobeNewswire November 1, 2018

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer

GlobeNewswire September 18, 2018
View More News ››

Opinion & Analysis (PINL:BVNKF)

Partnerships propel Stellar Biotechnologies' vaccine technology

The Life Sciences Report June 22, 2016

What Andy Grove and Michael Milken have taught us about prostate cancer

The Life Sciences Report April 20, 2016
View More Opinion ››

Bullboard Posts (PINL:BVNKF)

Be the first to post on this bullboard.

Vesalius Longevity Labs

Vesalius Longevity Labs

View More »

Podcasts